FDA’s “Critical Path”: Microbiologists Cite Barriers To Developing Anti-Infectives
This article was originally published in The Pink Sheet Daily
Executive Summary
American Society for Microbiology calls for more flexibility in risk/benefit assessments. FDA also is “uniquely positioned” to establish more reliable predictors of toxicity through data mining, ASM says.